Dr Benedikt Westphalen speaks to ecancer about the future of precision oncology.

There are several prerequisites to molecular profiling in cancer. This includes having access to quality-ensured testing, having the expertise to act on the results and gauging if the patients have access to the corresponding targeted treatment.

A few important questions need to be asked regarding the reasons behind testing and what will the outcome be.

Dr Westphalen further discusses clinical trials and how they can become the standard of care.

He concludes by talking about the potential of precision oncology and the direction it is headed.